BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced the appointment of Beth A. Krewson as Head of Legal.
Krewson is a legal and compliance leader in the life sciences industry with more than 20 years of experience, having served as an executive, counselor and business partner to company leaders and Boards of Directors. Her expertise spans legal, intellectual property (IP), business development, corporate governance and compliance matters. As Head of Legal, Krewson will be responsible for PharmaEssentia USA’s legal and compliance strategy to advance its leadership in myeloproliferative neoplasms (MPNs) and other hematological diseases.
“Beth is a respected executive attorney with a successful track record of building strong legal and compliance functions, supporting product development and launches and negotiating transactions,” said Dr. Ko-Chung Lin, PharmaEssentia Founder and Chief Executive Officer. “As PharmaEssentia continues to grow as a company, Beth’s integrity, creativity and expertise will enable us to further our mission to innovate for patients with MPNs who are in need of effective treatment options."
Prior to joining PharmaEssentia, Krewson served as the first in-house General Counsel at Formation Bio, where she empowered a legal and compliance team, oversaw patent strategy and an IP portfolio and advised senior management on corporate, clinical, manufacturing, finance, employment and contract matters. Before Formation Bio, Krewson was the Senior Vice President, General Counsel & Compliance Officer at BlueRock Therapeutics LP, where she built an integrated legal, IP and compliance function to support BlueRock’s business relationship with its parent company. While at BlueRock, she also served as secretary to the Board of Directors and advised the executive committee and senior management on matters of diverse legal, regulatory, compliance and commercial matters. Previously, she held General Counsel & Chief Compliance Officer positions at Innocoll Biotherapeutics N.A. Inc. and Churchill Pharmaceuticals LLC, as well as senior legal and compliance positions at Incyte Corporation, Celgene Corporation and GlaxoSmithKline.
Krewson received her J.D. from Suffolk University Law School and is a U.S. Patent and Trademark Office (USPTO) Registered Attorney with law licenses in Maryland, Washington, D.C. and Pennsylvania. Her appointment expands the PharmaEssentia U.S. leadership team, following the recent hiring of Fred Paster as Head of Commercial and promotion of Dr. Robert Geller to General Manager.
About PharmaEssentia
PharmaEssentia (TPEx: 6446), headquartered in Taipei, Taiwan, is a global and rapidly growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, PharmaEssentia aims to deliver effective new biologics for challenging diseases in the areas of hematology, oncology, and immunology with one approved product and a diversified pipeline. Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today PharmaEssentia is expanding its global presence with operations in the U.S., Japan, China, and Korea, along with a world-class biologics production facility in Taichung, Taiwan.
For more information about PharmaEssentia USA, visit our website, LinkedIn or Twitter.
Forward Looking Statement
This press release may contain forward looking statements, including statements regarding the clinical benefits to be derived from ropeginterferon alfa-2b, the commercial opportunity and competitive positioning, new indications or labeling for ropeginterferon alfa-2b, and business prospects for ropeginterferon alfa-2b. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and similar legislation and regulations under Taiwanese law. These forward-looking statements are based on management expectations and assumptions as of the date of this press release, and actual results may differ materially from those in these forward looking statements as a result of various factors. These factors include whether BESREMi is successfully commercialized and adopted by physicians and patients, the extent to which reimbursement is available for BESREMi, and the ability to receive FDA and other regulatory approvals for additional indications for BESREMi. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
© 2024 PharmaEssentia Corporation. All rights reserved.
PharmaEssentia, the PharmaEssentia logo, and BESREMi are trademarks or registered trademarks of PharmaEssentia Corporation.
